Press releases

CHEPLAPHARM's third capital market transaction five times oversubscribed

London/Greifswald, June 13, 2019 – CHEPLAPHARM Arzneimittel GmbH very successfully closed its third capital markets transaction within just one year....

Read more / pdf

Axia Best Managed Company Award goes to CHEPLAPHARM

Düsseldorf/Greifswald (DE), May 10, 2019 – CHEPLAPHARM Arzneimittel GmbH received the "Axia Best Managed Companies Award" (Axia BMC Award) yesterday....

Read more / pdf

CHEPLAPHARM celebrates topping-out ceremony

Just in time with the arrival of spring, CHEPLAPHARM Arzneimittel GmbH is celebrating the topping-out ceremony for the extension building at its...

Read more / pdf

By taking over the product rights for DORMICUM® and LEXOTAN®, CHEPLAPHARM closes the very successful fiscal year 2018

 

"As a perfect addition to an already extremely positive year for CHEPLAPHARM, we were able to start another large project in 2018 with F....

Read more / pdf

CHEPLAPHARM acquires product package from Bristol-Myers Squibb – significant expansion of our portfolio

CHEPLAPHARM Arzneimittel GmbH continues its successful expansion strategy by purchasing three further global niche products.

Read more / pdf

CHEPLAPHARM acquires global rights to Questran® from Bristol-Myers Squibb

CHEPLAPHARM Arzneimittel GmbH continues with its diversification strategy.

Read more / pdf

CHEPLAPHARM acquires product rights for ATACAND® and ATACAND® Plus from AstraZeneca in Europe

CHEPLAPHARM is pleased to announce the acquisition of the commercial rights to ATACAND® (Candesartan Cilexetil) and ATACAND® Plus (fixed-dose...

Read more / pdf